Double‑blind randomized study of oral glutamine on the management of radio/chemotherapy‑induced mucositis and dermatitis in head and neck cancer

Lopez‑Vaquero,David; Gutierrez‑Bayard,Lucia; Rodriguez‑Ruiz,Juan‑Andres; Saldaña‑Valderas,Monica; Infante‑Cossio,Pedro

doi:10.3892/mco.2017.1238

Double‑blind randomized study of oral glutamine on the management of radio/chemotherapy‑induced mucositis and dermatitis in head and neck cancer

Authors:
- David Lopez‑Vaquero
- Lucia Gutierrez‑Bayard
- Juan‑Andres Rodriguez‑Ruiz
- Monica Saldaña‑Valderas
- Pedro Infante‑Cossio
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Donostia University Hospital, 20014 San Sebastian, Spain, Department of Radiation Oncology, Puerta del Mar University Hospital, 11009 Cadiz, Spain, Department of Oral and Maxillofacial Surgery, Puerta del Mar University Hospital, 11009 Cadiz, Spain, Department of Clinical Pharmacology, Puerta del Mar University Hospital, 11009 Cadiz, Spain, Department of Surgery, School of Medicine, University of Seville, 41009 Seville, Spain
Published online on: May 5, 2017 https://doi.org/10.3892/mco.2017.1238
Pages: 931-936

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This randomized clinical trial was designed to determine whether glutamine administration was effective in reducing the incidence and severity of mucositis and dermatitis induced by radiotherapy (RT) or chemoradiotherapy (CHRT) in patients with head and neck cancer (HNC). Fifty patients were randomized to receive orally either L‑Glutamine or placebo (25 patients in each arm). In the glutamine‑treated group, 10 g of oral glutamine was administered three times daily. The primary endpoint was to compare the appearance of clinical mucositis between groups at the 6th week, according to the Common Terminology Criteria for Adverse Events. Secondary endpoints were: Functional mucositis, mucositis onset, cervicofacial dermatitis, pain, weight loss and assessment of quality of life (according to the M.D. Anderson Symptom Inventory‑Head and Neck). In total, 76 and 87.5% developed clinical mucositis in the glutamine and placebo group, respectively. The incidence and severity grade of mucositis at the 6th week did not exhibit statistically significantly differences between the two groups, although it had a higher value in the placebo group. Significant reduction of dermatitis incidence (P=0.038) and severity (P=0.032) was found in the glutamine group. There were no differences in other outcomes such as pain, weight loss and mucositis onset, in treatment parameters including concomitant chemotherapy, radiation dose and previous surgery, or in quality of life. The present study revealed that glutamine provided slight clinical effects compared with placebo in terms of reducing oral mucositis induced by RT or CHRT in patients with HNC at the 6th week; however, the results were not statistically significant. Although the findings suggested a significant benefit in reducing the incidence and severity of dermatitis, further confirmatory studies are required.

View Figures

View References

1	Moslemi D, Nokhandani AM, Otaghsaraei MT, Moghadamnia Y, Kazemi S and Moghadamnia AA: Management of chemo/radiation-induced oral mucositis in patients with head and neck cancer: A review of the current literature. Radiother Oncol. 120:13–20. 2016. View Article : Google Scholar : PubMed/NCBI
2	Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L and Zilberberg MD: Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol. 66:253–262. 2003. View Article : Google Scholar : PubMed/NCBI
3	Harada K, Ferdous T, Horinaga D, Uchida K, Mano T, Mishima K, Park S, Hanazawa H, Takahashi S, Okita A, et al: Efficacy of elemental diet on prevention for chemoradiotherapy-induced oral mucositis in patients with oral squamous cell carcinoma. Support Care Cancer. 24:953–959. 2016. View Article : Google Scholar : PubMed/NCBI
4	Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 350:1937–1944. 2004. View Article : Google Scholar : PubMed/NCBI
5	Elliott EA, Wright JR, Swann RS, Nguyen-Tân F, Takita C, Bucci MK, Garden AS, Kim H, Hug EB, Ryu J, et al: Phase III trial of an emulsion containing trolamine for the prevention of radiation dermatitis in patients with advanced squamous cell carcinoma of the head and neck: Results of radiation therapy oncology group trial 99–13. J Clin Oncol. 24:2092–2097. 2006. View Article : Google Scholar : PubMed/NCBI
6	Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, et al: High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiother Oncol. 90:166–171. 2009. View Article : Google Scholar : PubMed/NCBI
7	Mead GM: Management of oral mucositis associated with cancer chemotherapy. Lancet. 359:815–816. 2002. View Article : Google Scholar : PubMed/NCBI
8	Vélez I, Tamara LA and Mintz S: Management of oral mucositis induced by chemotherapy and radiotherapy: An update. Quintessence Int. 35:129–136. 2004.PubMed/NCBI
9	Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, et al: MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 120:1453–1461. 2014. View Article : Google Scholar : PubMed/NCBI
10	Stokman MA, Spijkervet FK, Boezen HM, Schouten JP, Roodenburg JL and de Vries EG: Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: Results of meta-analyses. J Dent Res. 85:690–700. 2006. View Article : Google Scholar : PubMed/NCBI
11	Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD and Peterson DE: Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 109:820–831. 2007. View Article : Google Scholar : PubMed/NCBI
12	Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L, Salzwimmer M, Lizambri R, Emmerson L, Chen MG and Berger D: Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: A randomized, placebo-controlled trial. J Clin Oncol. 29:2815–2820. 2011. View Article : Google Scholar : PubMed/NCBI
13	Xu JL, Xia R, Sun ZH, Sun L, Min X, Liu C, Zhang H and Zhu YM: Effects of honey use on the management of radio/chemotherapy-induced mucositis: A meta-analysis of randomized controlled trials. Int J Oral Maxillofac Surg. 45:1618–1625. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wischmeyer PE: Clinical applications of L-glutamine: Past, present, and future. Nutr Clin Pract. 18:377–385. 2003. View Article : Google Scholar : PubMed/NCBI
15	Neu J, DeMarco V and Li N: Glutamine: Clinical applications and mechanisms of action. Curr Opin Clin Nutr Metab Care. 5:69–75. 2002. View Article : Google Scholar : PubMed/NCBI
16	Skubitz KM and Anderson PM: Oral glutamine to prevent chemotherapy induced stomatitis: A pilot study. J Lab Clin Med. 127:223–228. 1996. View Article : Google Scholar : PubMed/NCBI
17	Silverman S Jr: Diagnosis and management of oral mucositis. J Support Oncol. 5 2 Suppl 1:S13–S21. 2007.
18	Savarese DM, Savy G, Vahdat L, Wischmeyer PE and Corey B: Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev. 29:501–513. 2003. View Article : Google Scholar : PubMed/NCBI
19	Choi K, Lee SS, Oh SJ, Lim SY, Lim SY, Jeon WK, Oh TY and Kim JW: The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr. 26:57–62. 2007. View Article : Google Scholar : PubMed/NCBI
20	Leung HW and Chan AL: Glutamine in alleviation of radiation-induced severe oral mucositis: A meta-analysis. Nutr Cancer. 68:734–742. 2016. View Article : Google Scholar : PubMed/NCBI
21	Huang EY, Leung SW, Wang CJ, Chen HC, Sun LM, Fang FM, Yeh SA, Hsu HC and Hsiung CY: Oral glutamine to alleviate radiation-induced oral mucositis: A pilot randomized trial. Int J Radiat Oncol Biol Phys. 46:535–539. 2000. View Article : Google Scholar : PubMed/NCBI
22	Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, Cabalar ME, Roth B, Negretti G, Sheinker B and Uchima P: Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head and-neck cancer. Int J Radiat Oncol Biol Phys. 65:1330–1337. 2006. View Article : Google Scholar : PubMed/NCBI
23	Chattopadhyay S, Saha A, Azam M, Mukherjee A and Sur PK: Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: A prospective randomized study. South Asian J Cancer. 3:8–12. 2014. View Article : Google Scholar : PubMed/NCBI
24	Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T, Tsugane M, Hayashi N, Maeda K, Inohara H, et al: L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: A double-blind, randomized, placebo-controlled trial. Oncol Rep. 33:33–39. 2015.PubMed/NCBI
25	Vidal-Casariego A, Calleja-Fernández A, Ballesteros-Pomar MD and Cano-Rodríguez I: Efficacy of glutamine in the prevention of oral mucositis and acute radiation induced esophagitis: A retrospective study. Nutr Cancer. 65:424–429. 2013. View Article : Google Scholar : PubMed/NCBI
26	Yarom N, Ariyawardana A, Hovan A, Barasch A, Jarvis V, Jensen SB, Zadik Y, Elad S, Bowen J and Lalla RV: Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO): Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer. 21:3209–3221. 2013. View Article : Google Scholar : PubMed/NCBI
27	Jebb SA, Osborne RJ, Maughan TS, Mohideen N, Mack P, Mort D, Shelley MD and Elia M: 5-fluorouracil and folinic acid induced mucositis: No effect of oral glutamine supplementation. Br J Cancer. 70:732–735. 1994. View Article : Google Scholar : PubMed/NCBI
28	Anderson PM, Schroeder G and Skubitz KM: Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 83:1433–1439. 1998. View Article : Google Scholar : PubMed/NCBI
29	Okuno SH, Woodhouse CO, Loprinzi CL, Sloan JA, LaVasseur BI, Clemens-Schutjer D, Swan D, Axvig C, Ebbert LP, Tirona MR, et al: Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol. 22:258–261. 1999. View Article : Google Scholar : PubMed/NCBI
30	Ward E, Smith M, Henderson M, Reid U, Lewis I, Kinsey S, Allgar V, Bowers D and Picton SV: The effect of high-dose enteral glutamine on the incidence and severity of mucositis in paediatric oncology patients. Eur J Clin Nutr. 63:134–140. 2009. View Article : Google Scholar : PubMed/NCBI
31	Rubio IT, Cao Y, Hutchins LF, Westbrook KC and Klimberg VS: Effect of glutamine on methotrexate efficacy and toxicity. Ann Surg. 227:772–778; 778–780. 1998. View Article : Google Scholar : PubMed/NCBI
32	Cockerham MB, Weinberger BB and Lerchie SB: Oral glutamine for the prevention of oral mucositis associated with high-dose paclitaxel and melphalan for autologous bone marrow transplantation. Ann Pharmacother. 34:300–303. 2000. View Article : Google Scholar : PubMed/NCBI
33	Peterson DE, Jones JB and Petit RG II: Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 109:322–331. 2007. View Article : Google Scholar : PubMed/NCBI
34	Imai T, Matsuura K, Asada Y, Sagai S, Katagiri K, Ishida E, Saito D, Sadayasu R, Wada H and Saijo S: Effect of HMB/Arg/Gln on the prevention of radiation dermatitis in head and neck cancer patients treated with concurrent chemoradiotherapy. Jpn J Clin Oncol. 44:422–427. 2014. View Article : Google Scholar : PubMed/NCBI